Background: Colorectal cancer (CRC) is a common malignancy of the digestive system, but its specific mechanisms of occurrence and development remain incompletely understood. F-Box and leucine-rich repeat protein 7 (FBXL7) is a subunit of the Skp-cullin-F-box ubiquitin ligase, involved in cell cycle regulation, endothelial cell damage, and inflammatory immunological responses. However, the role of FBXL7 in CRC remains unknown. In this study, we investigated the clinical significance and potential mechanism of FBXL7 expression in CRC progression. Methods: We utilized data from The Cancer Genome Atlas (TCGA) and the University of California Santa Cruz Xena (UCSC Xena) database for bioinformatic analyses. Clinical CRC samples were used to confirm FBXL7 expression. Gene set enrichment analysis (GSEA) and various databases, such as TCGA, UCSC Xena, cBioPortal, University of ALabama at Birmingham CANcer data analysis portal, MethSurv, Tumor Immune Estimation Resource (TIMER), TIMER2.0, Tumor-Immune System Interaction Database, and Tumor Immune Dysfunction and Exclusion Database (TIDB), were used to investigate the role of FBXL7 in CRC. Statistical analysis was performed using R (v.3.6.3) or GraphPad Prism 8.0. Results: Our findings revealed the predictive significance of FBXL7 in CRC patients. FBXL7 expression was associated with tumor stage, lymph node stage, pathological stage, perineural invasion, and lymphatic invasion. GSEA analysis identified associations between FBXL7 and extracellular matrix organization, as well as immune-related pathways. Immunological analysis revealed a correlation between high FBXL7 expression and the development of an immunosuppressive microenvironment. Conclusion: Identifying FBXL7 as a novel biomarker for CRC could shed light on the promotion of CRC development by the immune environment.

中文翻译：

---

F-Box 和富含亮氨酸的重复蛋白 7 是一种预后生物标志物，与结直肠癌的免疫抑制微环境相关。

背景：结直肠癌（CRC）是消化系统常见的恶性肿瘤，但其发生、发展的具体机制尚不完全清楚。F-Box 和富含亮氨酸的重复蛋白 7 (FBXL7) 是 Skp-cullin-F-box 泛素连接酶的亚基，参与细胞周期调节、内皮细胞损伤和炎症免疫反应。然而，FBXL7 在 CRC 中的作用仍不清楚。在本研究中，我们研究了 FBXL7 表达在 CRC 进展中的临床意义和潜在机制。方法：我们利用癌症基因组图谱 (TCGA) 和加州大学圣克鲁斯 Xena (UCSC Xena) 数据库的数据进行生物信息学分析。使用临床 CRC 样本来确认 FBXL7 表达。基因集富集分析（GSEA）和各种数据库，如TCGA、UCSC Xena、cBioPortal、阿拉巴马大学伯明翰分校CANcer数据分析门户、MethSurv、肿瘤免疫估计资源（TIMER）、TIMER2.0、肿瘤免疫系统相互作用数据库、肿瘤免疫功能障碍和排除数据库 (TIDB) 用于研究 FBXL7 在 CRC 中的作用。使用 R (v.3.6.3) 或 GraphPad Prism 8.0 进行统计分析。结果：我们的研究结果揭示了 FBXL7 对 CRC 患者的预测意义。FBXL7表达与肿瘤分期、淋巴结分期、病理分期、神经周围侵犯和淋巴管侵犯相关。GSEA 分析确定了 FBXL7 与细胞外基质组织以及免疫相关途径之间的关联。免疫学分析揭示了 FBXL7 高表达与免疫抑制微环境的发展之间的相关性。结论：将 FBXL7 鉴定为 CRC 的新型生物标志物可以揭示免疫环境促进 CRC 发展的情况。